Cancer Science & Therapy

ISSN: 1948-5956

Open Access

Optimizations of anti-PEG sandwich ELISA for quantification of PEGylated molecules

Global Summit on Oncology & Cancer

May 25-27, 2017 Osaka, Japan

Ming-yang Tseng

Kaohsiung Medical University, Taiwan

Posters & Accepted Abstracts: J Cancer Sci Ther

Abstract :

Food and Drug Administration (FDA, USA) has approved the PEGylated technology that can be used in clinical treatment. With the times, numbers of PEGylated molecule has entered to clinical use, such as protein, liposome and small molecule. In previous study, we have established an anti-PEG sandwich ELISA (AGP4/3-3-Biotin) that can quantify the PEGylated compounds. However, the sensitivity of this PEG quantification platform might be affected that depend on the different kinds of the PEGylated molecules. In this study, we established an anti-PEG sandwich ELISA according to different combination of the high affinity anti-PEG antibodies that can provide extensive quantification to any kind of PEGylated compound.

Biography :

Ming-yang Tseng received his Bachelor of Science Degree from I-Shou University, with a major in Biomedical Engineering. He completed Master’s degree from Kaohsiung Medical University and PhD degree at the Graduate Institute of Medicine in Kaohsiung Medical University. He is working on the characterization and development of antibodies in the laboratory of Dr. Tian-Lu Cheng.

Email: [email protected]

Recommended Conferences

Cancer Meet 2020

San Francisco, USA
arrow_upward arrow_upward